BioSpace News Archive

More Than a Dozen Additional Organizations Have Already Begun the Application Process

CASI Pharmaceuticals, Inc. announces that it has entered into framework agreements to build a state-of-the-art manufacturing site strategically located in the Wuxi Huishan Economic Development Zone in Jiangsu Province, China.

4D Molecular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to 4D-110 for the treatment of choroideremia.

As the holidays approach, American Addiction Centers (AAC) releases 10 tips to help those in recovery stay sober during the season.

In a life-changing joint effort, eight dentists, three dental hygienists, four dental assistants and two support team members from Aspen Dental-branded practices, the nation’s largest and fastest-growing branded network of dental care providers, and Global Dental Relief journeyed to Antigua, Guatemala with a unified mission to deliver crucial dental care and oral health education to more than 740 local school children.

Volpara Solutions, Inc. will showcase its latest artificial intelligence (AI) updates at the upcoming 104th Annual Radiological Society of North America (RSNA) meeting, November 25–30, 2018 (South Hall #2565).

United Imaging Healthcare Co., Ltd. (UIH), an international leader in advanced medical imaging and radiotherapy equipment, today announced the appointment of Hermann Requardt, Ph.D., former Chief Executive Officer of Siemens Healthcare, as its Senior Scientific Advisor. Prof. Dr. Requardt will provide strategic guidance on business, technology and R&D globally.

Seqirus, a global leader in influenza prevention, today released a new real-world evidence analysis indicating that its cell-based quadrivalent influenza vaccine (QIVc) was 36.2 percent more effective than standard egg-based quadrivalent vaccine (QIVe) in preventing influenza-like illness

United States Army Veteran Donna Zephrine describes her deployment to Iraq in jagged excerpts of fragmented memory and anxiety. Her mind plays a nonstop soundtrack of war:

Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, today announced it has completed Phase 1 single ascending dose and multiple ascending dose studies for its lead compound, SXC-2023.